Product Description
Mechanisms of Action: CCR5 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Acquired Immunodeficiency Syndrome|HIV Infections
Phase 2: HIV Infections|Colorectal Cancer|Acquired Immunodeficiency Syndrome
Phase 1: HIV Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MK-7690-046 | P2 |
Completed |
Colorectal Cancer |
2021-06-08 |
|
| MTN-027 | P1 |
Completed |
HIV Infections |
2016-03-01 |
|
| VICTOR-E4 | P3 |
Terminated |
HIV Infections |
2010-10-26 |
|
| P04100 | P2 |
Completed |
HIV Infections |
2010-10-21 |